Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Achaogen Company

AKAOQ
US0044491043
A1XFMJ

Price

0.03
Today +/-
+0
Today %
+0 %
P

Achaogen stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Achaogen stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Achaogen stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Achaogen stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Achaogen's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Achaogen Stock Price History

DateAchaogen Price
6/21/20210.03 undefined
6/18/20210.03 undefined

Achaogen Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Achaogen, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Achaogen from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Achaogen’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Achaogen. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Achaogen’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Achaogen’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Achaogen’s growth potential.

Achaogen Revenue, EBIT and net profit per share

DateAchaogen RevenueAchaogen EBITAchaogen Net Income
2020e2.96 M undefined0 undefined-383.28 M undefined
2019e5.26 M undefined0 undefined-319.4 M undefined
20188.73 M undefined-165.65 M undefined-186.51 M undefined
201711.18 M undefined-126.33 M undefined-125.62 M undefined
201641.77 M undefined-49.35 M undefined-71.23 M undefined
201526.06 M undefined-26.57 M undefined-27.09 M undefined
201419.97 M undefined-19.79 M undefined-20.18 M undefined
201318.51 M undefined-11.96 M undefined-13.11 M undefined
201217.94 M undefined-15.99 M undefined-18.37 M undefined
201122.47 M undefined-20.72 M undefined-20.87 M undefined

Achaogen Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201120122013201420152016201720182019e2020e
22171819264111852
--22.735.885.5636.8457.69-73.17-27.27-37.50-60.00
-------100.00--
0000000800
-20-15-11-19-26-49-126-16500
-90.91-88.24-61.11-100.00-100.00-119.51-1,145.45-2,062.50--
-20-18-13-20-27-71-125-186-319-383
--10.00-27.7853.8535.00162.9676.0648.8071.5120.06
15.7815.7815.7814.2118.1523.7139.6545.3800
----------
Details

Keystats

ⓘ

Revenue and Growth

The Achaogen Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Achaogen is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (k)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20112012201320142015201620172018
               
12.57.110.763.6858.73145.88164.7930.96
4.94.37.25.235.0412.151.361.86
00000000
0000000515
0.50.41.90.521.722.3212.2627.92
17.911.819.869.4365.49160.34178.4161.25
1.31.30.70.730.913.2614.812.47
00000000
00000000
00000000
00000000
0.30.20.20.160.470.323.8618.57
1.61.50.90.891.373.5818.6721.04
19.513.320.770.3266.86163.93197.0782.29
               
100.4100.4132.30.020.020.040.040.05
234.1213.53219.18353.93494.76553.02
-97.2-115.6-128.7-148.9-175.99-247.22-372.84-559.35
000-0.03-0.05-0.0100
00000000
5.2-12.27.764.6143.16106.74121.96-6.29
2.92.92.92.123.545.746.8612.47
3.51.633.274.939.715.4415.23
0.30.30.10.130.230.12.10.96
00000000
0.47.25004.1712.549.78
7.112115.528.6919.7136.978.45
6.611.81.7014.5421.1119.460
00000000
0.61.70.40.190.4816.3718.7510.13
7.213.52.10.1915.0137.4838.2110.13
14.325.513.15.7123.757.1975.1188.58
19.513.320.870.3266.86163.93197.0782.29
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Achaogen provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Achaogen's financial health and stability.

Assets

Achaogen's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Achaogen must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Achaogen after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Achaogen's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20112012201320142015201620172018
-20-18-13-20-27-71-125-186
00000012
00000000
2-1-321016-7
02123241226
00000121
00000000
-17-16-13-14-21-46-95-165
-100000-7-9
-100-45510011
000-45511720
00000000
311-4-61410-426
002274212513428
31117671713513055
--------
00000000
-14-53819835-98
00000000
00000000

Achaogen stock margins

The Achaogen margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Achaogen. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Achaogen.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Achaogen's sales revenue. A higher gross margin percentage indicates that the Achaogen retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Achaogen's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Achaogen's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Achaogen's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Achaogen. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Achaogen's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Achaogen Margin History

Achaogen Gross marginAchaogen Profit marginAchaogen EBIT marginAchaogen Profit margin
2020e99.64 %0 %-12,930.2 %
2019e99.64 %0 %-6,070.17 %
201899.64 %-1,897.88 %-2,136.94 %
201799.64 %-1,130.43 %-1,124.1 %
201699.64 %-118.13 %-170.51 %
201599.64 %-101.96 %-103.96 %
201499.64 %-99.08 %-101.03 %
201399.64 %-64.61 %-70.83 %
201299.64 %-89.13 %-102.4 %
201199.64 %-92.21 %-92.88 %

Achaogen Stock Sales Revenue, EBIT, Earnings per Share

The Achaogen earnings per share therefore indicates how much revenue Achaogen has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Achaogen earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Achaogen's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Achaogen’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Achaogen's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Achaogen Revenue, EBIT and net profit per share

DateAchaogen Sales per ShareAchaogen EBIT per shareAchaogen Earnings per Share
2020e0.05 undefined0 undefined-6 undefined
2019e0.08 undefined0 undefined-5 undefined
20180.19 undefined-3.65 undefined-4.11 undefined
20170.28 undefined-3.19 undefined-3.17 undefined
20161.76 undefined-2.08 undefined-3 undefined
20151.44 undefined-1.46 undefined-1.49 undefined
20141.41 undefined-1.39 undefined-1.42 undefined
20131.17 undefined-0.76 undefined-0.83 undefined
20121.14 undefined-1.01 undefined-1.16 undefined
20111.42 undefined-1.31 undefined-1.32 undefined

Achaogen business model

Achaogen Inc is an innovative biotechnology company specializing in the development of antibiotics for the treatment of life-threatening infectious diseases. The company's business model is based on research and development of new antibiotics, aiming to improve medical care for patients with infections. Achaogen was founded in 2002 by a team of researchers and professionals in the biotechnology industry and has developed several products for the treatment of diseases such as pneumonia, urinary tract infections, and bloodstream infections. The company's main divisions include Plazomicin, Zemdri, and C-Scape, which are antibiotics targeting different types of infections. Achaogen is one of the most popular companies on Eulerpool.com.

Achaogen SWOT Analysis

Strengths

1. Strong portfolio of innovative antibiotic drugs.

2. Patented technology and intellectual property rights.

3. Skilled and experienced research and development team.

4. Strong financial performance and revenue growth.

Weaknesses

1. Relatively small market share compared to larger pharmaceutical companies.

2. Dependence on a limited number of key drugs for revenue generation.

3. Costly and time-consuming regulatory approval process.

4. Vulnerability to patent expirations and generic competition.

Opportunities

1. Increasing global prevalence of antibiotic-resistant infections.

2. Growing demand for effective antibiotics in emerging markets.

3. Collaboration opportunities with other pharmaceutical companies.

4. Potential for expansion into related therapeutic areas.

Threats

1. Intense competition within the antibiotics market.

2. Regulatory uncertainties and changing government policies.

3. Potential negative public perception of antibiotics and their overuse.

4. Risk of emerging superbugs with resistance to existing antibiotics.

Achaogen Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Achaogen historical P/E ratio, EBIT multiple, and P/S ratio

Achaogen shares outstanding

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Achaogen earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Achaogen's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Achaogen’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Achaogen's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Achaogen.

Most common questions regarding Achaogen

What values and corporate philosophy does Achaogen represent?

Achaogen Inc represents values of innovation, dedication, and patient-centeredness. As a leading biopharmaceutical company, Achaogen Inc is committed to developing and commercializing innovative antibacterial treatments to address the urgent global health threats posed by multi-drug resistant infections. With a corporate philosophy centered around advancing the standard of care for patients, Achaogen Inc strives to provide effective and safe antibiotics that target bacteria resistant to traditional treatment options. By leveraging cutting-edge research and development technologies, Achaogen Inc aims to make a positive impact on public health by addressing the unmet medical needs of patients suffering from serious infections.

In which countries and regions is Achaogen primarily present?

Achaogen Inc is primarily present in the United States, focusing on the development and commercialization of innovative antibacterial treatments.

What significant milestones has the company Achaogen achieved?

Achaogen Inc. has achieved several significant milestones in its history. The company successfully developed ZEMDRI® (plazomicin), an antibiotic used for the treatment of adults with complicated urinary tract infections (cUTI) including pyelonephritis. In addition, Achaogen Inc. secured FDA approval for ZEMDRI® in June 2018, becoming the company's first commercialized product. The accomplishment showcased the company's capabilities in developing innovative therapies to combat serious infections. Achaogen Inc. also secured multiple grants and collaborations, including support from the Biomedical Advanced Research and Development Authority (BARDA) and partnerships with other healthcare organizations. These achievements reflect the company's commitment to addressing critical medical needs and advancing the field of antibiotic research and development.

What is the history and background of the company Achaogen?

Achaogen Inc is a biopharmaceutical company based in South San Francisco, California. Founded in 2002, the company specializes in the discovery, development, and commercialization of innovative antibacterial treatments. Achaogen Inc is dedicated to addressing the growing threat of antibiotic resistance by utilizing its expertise in research and development. With a focus on serious infections caused by multidrug-resistant bacteria, the company aims to provide patients with groundbreaking therapeutic options. Over the years, Achaogen Inc has made significant advancements in the field of antibacterial treatments, cementing its position as a leader in the industry.

Who are the main competitors of Achaogen in the market?

The main competitors of Achaogen Inc in the market are pharmaceutical companies focused on the development and commercialization of antibiotics and antimicrobial agents. Some notable competitors include Merck & Co., Pfizer Inc., GlaxoSmithKline, Novartis AG, and Roche Holding AG. These companies, like Achaogen Inc, are actively engaged in the research, development, and commercialization of innovative therapies to combat antibiotic-resistant infections. They compete for market share and strive to address unmet medical needs in the field of infectious diseases.

In which industries is Achaogen primarily active?

Achaogen Inc is primarily active in the pharmaceutical industry.

What is the business model of Achaogen?

The business model of Achaogen Inc revolves around developing and commercializing innovative antibacterial therapies for serious infections caused by multidrug-resistant bacteria. Achaogen Inc focuses on discovering and developing drugs that target bacterial pathogens resistant to existing antibiotics. The company aims to address the urgent need for new antibiotics through its research and development efforts. By leveraging its expertise in antibiotic drug discovery and development, Achaogen Inc strives to provide new treatment options for patients and healthcare providers combating drug-resistant infections.

What is the P/E ratio of Achaogen 2024?

The P/E ratio cannot be calculated for Achaogen at the moment.

What is the P/S ratio of Achaogen 2024?

The P/S cannot be calculated for Achaogen currently.

What is the Quality Investing of Achaogen?

The Quality Investing for Achaogen is 3/10.

What is the revenue of Achaogen 2024?

The revenue cannot currently be calculated for Achaogen.

How high is the profit of Achaogen 2024?

The profit cannot currently be calculated for Achaogen.

What is the business model of Achaogen

Achaogen Inc. is a biopharmaceutical company focused on the development and commercialization of innovative antibiotics for the treatment of severe bacterial infections. The company was founded in 2002 and is headquartered in South San Francisco, California. Achaogen has a diverse portfolio of products, including Zemdri, the only approved intravenous antibiotic for the treatment of patients with complicated urinary tract infections (cUTI) when other antibiotics do not work. It is also a significant partner in public health and offers specialized consulting services for clinical microbiology and infection control. Achaogen's business model is focused on the discovery and development of antibiotics against antibiotic resistance and serious infectious diseases. The company aims to bring new antibiotics to market to meet the growing need for effective antibiotics that are effective against bacterial infections that have become resistant to conventional antibiotics. Achaogen uses a unique business model that focuses on three main areas: the discovery and development of novel antibiotics for MDR infections, the clinical development of antibiotics, and innovative services for microbiologists and infection control professionals. Overall, Achaogen's business model has proven successful, particularly in the face of advancing antibiotic resistance. The company understands the importance of continued research and development of antibiotics and is committed to providing new and innovative solutions for severe bacterial infections. Through its unique research and development strategy, clinical development, and comprehensive services, Achaogen Inc. has a strong position in the field of antibiotic research and development.

What is the Achaogen dividend?

Achaogen pays a dividend of 0 USD distributed over payouts per year.

How often does Achaogen pay dividends?

The dividend cannot currently be calculated for Achaogen or the company does not pay out a dividend.

What is the Achaogen ISIN?

The ISIN of Achaogen is US0044491043.

What is the Achaogen WKN?

The WKN of Achaogen is A1XFMJ.

What is the Achaogen ticker?

The ticker of Achaogen is AKAOQ.

How much dividend does Achaogen pay?

Over the past 12 months, Achaogen paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Achaogen is expected to pay a dividend of 0 USD.

What is the dividend yield of Achaogen?

The current dividend yield of Achaogen is .

When does Achaogen pay dividends?

Achaogen pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Achaogen?

Achaogen paid dividends every year for the past 0 years.

What is the dividend of Achaogen?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Achaogen located?

Achaogen is assigned to the 'Health' sector.

Wann musste ich die Aktien von Achaogen kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Achaogen from 10/21/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/21/2024.

When did Achaogen pay the last dividend?

The last dividend was paid out on 10/21/2024.

What was the dividend of Achaogen in the year 2023?

In the year 2023, Achaogen distributed 0 USD as dividends.

In which currency does Achaogen pay out the dividend?

The dividends of Achaogen are distributed in USD.

All fundamentals about Achaogen

Our stock analysis for Achaogen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Achaogen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.